Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in lymphoma show the therapy can “leapfrog” the competition. The biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback